Harmony Biosciences (HRMY) to Release Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Harmony Biosciences to post earnings of $0.84 per share and revenue of $240.0360 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock opened at $36.01 on Tuesday. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. The stock’s fifty day moving average price is $37.48 and its 200-day moving average price is $34.32. The firm has a market cap of $2.07 billion, a P/E ratio of 11.32, a P/E/G ratio of 0.33 and a beta of 0.84. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of research reports. Zacks Research raised shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Oppenheimer reissued an “outperform” rating and issued a $62.00 price objective on shares of Harmony Biosciences in a research note on Monday, November 24th. Mizuho upped their target price on Harmony Biosciences from $39.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, December 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, December 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $45.63.

Insider Buying and Selling at Harmony Biosciences

In related news, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Sandip Kapadia sold 20,961 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $35.92, for a total value of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,640 shares of company stock worth $1,932,256 over the last ninety days. Corporate insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

Several institutional investors have recently added to or reduced their stakes in HRMY. Nebula Research & Development LLC increased its holdings in shares of Harmony Biosciences by 2.0% during the second quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock valued at $550,000 after acquiring an additional 348 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Harmony Biosciences by 2.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,686 shares of the company’s stock worth $717,000 after purchasing an additional 532 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Harmony Biosciences by 30.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,663 shares of the company’s stock valued at $100,000 after purchasing an additional 619 shares in the last quarter. Cetera Investment Advisers increased its stake in Harmony Biosciences by 9.8% during the 2nd quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock valued at $266,000 after purchasing an additional 748 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Harmony Biosciences by 0.3% in the second quarter. Bank of America Corp DE now owns 270,220 shares of the company’s stock worth $8,539,000 after buying an additional 898 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.